Activity ratios measure how efficiently a company performs day-to-day tasks, such us the collection of receivables and management of inventory.
Paying user area
Try for free
Vertex Pharmaceuticals Inc. pages available for free this week:
- Income Statement
- Balance Sheet: Assets
- Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
- Analysis of Liquidity Ratios
- Analysis of Short-term (Operating) Activity Ratios
- Enterprise Value to EBITDA (EV/EBITDA)
- Price to FCFE (P/FCFE)
- Operating Profit Margin since 2005
- Return on Assets (ROA) since 2005
- Total Asset Turnover since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Vertex Pharmaceuticals Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Long-term Activity Ratios (Summary)
Based on: 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
The analysis of the financial turnover ratios over the periods from March 31, 2020, through June 30, 2025, reveals several notable trends and patterns concerning asset and equity utilization.
- Net Fixed Asset Turnover
- The net fixed asset turnover ratio shows a consistent upward trend starting at 6.47 in March 2021 and rising to a peak of 9.51 by September 2024. There is a slight decline afterward, settling around 8.55 by June 2025. This gradual increase suggests improved efficiency in generating sales from fixed assets over time, with the company increasingly leveraging its fixed assets to drive revenue.
- Net Fixed Asset Turnover (Including Operating Lease, Right-of-Use Asset)
- When incorporating operating leases and right-of-use assets, the net fixed asset turnover ratio begins at 4.83 in March 2021, rising steadily to 6.86 by June 2024. However, there is a sharp decline to approximately 4.21–4.31 in the subsequent quarters leading to June 2025. The initial increase indicates growing utilization of both owned and leased fixed assets, but the later decrease may reflect changes in lease arrangements or asset base revaluation affecting turnover efficiency.
- Total Asset Turnover
- The total asset turnover ratio remains relatively stable but exhibits a mild downward trend from 0.53 in March 2021 to a low of about 0.43 by June 2024. A slight recovery occurs thereafter, reaching approximately 0.49 in mid-2025. This suggests that overall asset utilization to generate revenue has slightly weakened but partly rebounds toward the latest periods.
- Equity Turnover
- The equity turnover ratio follows a similar pattern, starting around 0.71 in early 2021, decreasing steadily to 0.55 in mid-2024, and then recovering to about 0.66 by mid-2025. This indicates changes in how effectively the company is using shareholder equity to drive sales, with a period of declining efficiency followed by a moderate improvement.
In summary, there has been a marked improvement in fixed asset efficiency, particularly in net fixed asset turnover excluding leases, signaling strong asset management in this category. However, total assets and equity turnovers show a slight decline over several periods, possibly reflecting broader asset base changes or shifts in capital structure that impacted overall asset and equity productivity. The decrease in turnover including operating leases in the latest periods points to potential adjustments in lease accounting or asset usage strategies that warrant further investigation.
Net Fixed Asset Turnover
Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | |||||||||||||||||||||||||||||
Revenues | |||||||||||||||||||||||||||||
Property and equipment, net | |||||||||||||||||||||||||||||
Long-term Activity Ratio | |||||||||||||||||||||||||||||
Net fixed asset turnover1 | |||||||||||||||||||||||||||||
Benchmarks | |||||||||||||||||||||||||||||
Net Fixed Asset Turnover, Competitors2 | |||||||||||||||||||||||||||||
AbbVie Inc. | |||||||||||||||||||||||||||||
Amgen Inc. | |||||||||||||||||||||||||||||
Bristol-Myers Squibb Co. | |||||||||||||||||||||||||||||
Danaher Corp. | |||||||||||||||||||||||||||||
Eli Lilly & Co. | |||||||||||||||||||||||||||||
Gilead Sciences Inc. | |||||||||||||||||||||||||||||
Johnson & Johnson | |||||||||||||||||||||||||||||
Merck & Co. Inc. | |||||||||||||||||||||||||||||
Pfizer Inc. | |||||||||||||||||||||||||||||
Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||||||||
Thermo Fisher Scientific Inc. |
Based on: 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q2 2025 Calculation
Net fixed asset turnover
= (RevenuesQ2 2025
+ RevenuesQ1 2025
+ RevenuesQ4 2024
+ RevenuesQ3 2024)
÷ Property and equipment, net
= ( + + + )
÷ =
2 Click competitor name to see calculations.
- Revenue Trends
- Revenues demonstrate a consistent upward trend over the entire period analyzed. Starting at approximately 1.52 billion USD in the first quarter of 2020, revenues steadily increase, reaching a peak slightly above 2.91 billion USD in the fourth quarter of 2024. Notably, there are minor quarter-to-quarter fluctuations, such as a small decline in the fourth quarter of 2022, but these are followed by recoveries in subsequent quarters. The growth pace appears to accelerate from early 2023 onwards, indicating strengthening sales or successful market expansion.
- Property and Equipment, Net
- The net value of property and equipment shows a general upward trend, increasing from 736 million USD in the first quarter of 2020 to about 1.34 billion USD by the fourth quarter of 2025. Some volatility is visible, specifically minor decreases in certain quarters (e.g., a decrease from the third to the fourth quarter of 2022 and again in late 2024), but the overall progression reflects ongoing capital investment or asset acquisition. This fixed asset base expansion aligns with the growth in revenues over time.
- Net Fixed Asset Turnover Ratio
- The net fixed asset turnover ratio, available from the third quarter of 2020 onwards, indicates the efficiency with which the company uses its fixed assets to generate sales. It starts at around 6.47 and generally increases throughout the period, reaching a high of approximately 9.5 in the third quarter of 2024. This rising ratio implies improving operational efficiency or better utilization of fixed assets, as the company generates more revenue per unit of net fixed asset value. However, slight decreases and fluctuations occur toward the end of the timeframe, suggesting possible short-term shifts in asset use or revenue generation dynamics.
- Summary Analysis
- Overall, the data reflect positive financial momentum. Revenue growth combined with expanding property and equipment values suggests ongoing business scaling and capital investment. The enhancement in net fixed asset turnover ratio underscores improved asset efficiency, contributing to revenue increases. These trends indicate effective management of both sales expansion and fixed asset utilization, supporting sustained performance improvements. Occasional fluctuations in revenues and asset values are relatively minor and do not detract from the prevailing upward trajectories.
Net Fixed Asset Turnover (including Operating Lease, Right-of-Use Asset)
Vertex Pharmaceuticals Inc., net fixed asset turnover (including operating lease, right-of-use asset) calculation (quarterly data)
Based on: 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q2 2025 Calculation
Net fixed asset turnover (including operating lease, right-of-use asset)
= (RevenuesQ2 2025
+ RevenuesQ1 2025
+ RevenuesQ4 2024
+ RevenuesQ3 2024)
÷ Property and equipment, net (including operating lease, right-of-use asset)
= ( + + + )
÷ =
- Revenues
- The revenue figures show a general upward trend from March 31, 2020, through June 30, 2024. Starting at approximately $1.52 billion in early 2020, revenues steadily increased, peaking at about $2.91 billion in the fourth quarter of 2024. There are minor fluctuations within quarters, but the overall pattern reflects consistent growth, with a slight dip occurring in the second quarter of 2025. This growth suggests expansion in sales or pricing power over the observed period.
- Property and equipment, net (including operating lease, right-of-use asset)
- The net value of property and equipment exhibits a steady increase throughout the time series, starting at roughly $736 million in early 2020 and rising to approximately $2.65 billion by the second quarter of 2025. Notable acceleration in asset value is observed from mid-2023 onwards, with a marked increase between June 2024 and December 2024, indicating significant capital investment or acquisitions. The growth in fixed assets outpaces the revenue growth rate, especially in the latter periods.
- Net fixed asset turnover (including operating lease, right-of-use asset)
- The net fixed asset turnover ratio, which indicates how efficiently the company uses its fixed assets to generate revenue, starts being recorded in the fourth quarter of 2020 at 4.83. This ratio increases steadily over the next three years, reaching a peak of 6.86 by June 2024. This upward trend suggests improving efficiency in asset utilization during this period. However, from June 2024 through June 2025, a notable decline in turnover is observed, dropping to around 4.21 by September 2025. This decline coincides with a large increase in property and equipment values, implying that asset growth is currently outpacing revenue generation, which may reflect either new asset deployment lagging in productivity or other operational inefficiencies developing in this late period.
Total Asset Turnover
Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | |||||||||||||||||||||||||||||
Revenues | |||||||||||||||||||||||||||||
Total assets | |||||||||||||||||||||||||||||
Long-term Activity Ratio | |||||||||||||||||||||||||||||
Total asset turnover1 | |||||||||||||||||||||||||||||
Benchmarks | |||||||||||||||||||||||||||||
Total Asset Turnover, Competitors2 | |||||||||||||||||||||||||||||
AbbVie Inc. | |||||||||||||||||||||||||||||
Amgen Inc. | |||||||||||||||||||||||||||||
Bristol-Myers Squibb Co. | |||||||||||||||||||||||||||||
Danaher Corp. | |||||||||||||||||||||||||||||
Eli Lilly & Co. | |||||||||||||||||||||||||||||
Gilead Sciences Inc. | |||||||||||||||||||||||||||||
Johnson & Johnson | |||||||||||||||||||||||||||||
Merck & Co. Inc. | |||||||||||||||||||||||||||||
Pfizer Inc. | |||||||||||||||||||||||||||||
Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||||||||
Thermo Fisher Scientific Inc. |
Based on: 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q2 2025 Calculation
Total asset turnover
= (RevenuesQ2 2025
+ RevenuesQ1 2025
+ RevenuesQ4 2024
+ RevenuesQ3 2024)
÷ Total assets
= ( + + + )
÷ =
2 Click competitor name to see calculations.
- Revenues
- Revenues displayed a generally consistent upward trend from March 31, 2020, through June 30, 2024, increasing from approximately 1.52 billion US dollars to a peak near 2.91 billion US dollars. There was steady growth each quarter, with minor fluctuations observed in the fourth quarters of 2022 and 2023, where revenues slightly decreased compared to the preceding quarter. Overall, this suggests sustained business expansion and effective revenue generation over the analyzed period.
- Total Assets
- Total assets showed a strong and continuous increase over the entire timeline, rising from about 8.89 billion US dollars in the first quarter of 2020 to approximately 24.04 billion US dollars by mid-2025. This reflects ongoing accumulation of resources or investments, with notable acceleration in asset growth particularly after 2021, indicating possible expansion in capacity or acquisition activity. Slight declines or volatility in asset values occur around late 2023 to mid-2024, but the general long-term trajectory remains upward.
- Total Asset Turnover
- The total asset turnover ratio, starting from being unavailable in early periods, became available from the third quarter of 2020 onward and fluctuated within a narrow range of approximately 0.43 to 0.57. Initially, turnover ratios improved from roughly 0.53 to 0.57 across 2020 and 2021, suggesting more efficient use of assets. However, from late 2021 through mid-2024, the ratio generally declined to the lower end around 0.43 to 0.44, indicating a decrease in how effectively assets were used to generate revenues. Towards mid-2024 and beyond, the ratio showed some recovery, climbing again to approximately 0.48 to 0.51. This pattern indicates periods of both improving and weakening asset utilization efficiency, with a recent rebound suggesting partial restoration of operational efficiency.
- Overall Analysis
- Throughout the analyzed quarters, the company experienced consistent revenue growth alongside substantial asset base expansion. This combination typically suggests strategic investments or scaling of operations. However, the declining trend in total asset turnover ratios during a significant portion of this timeframe may imply that asset growth somewhat outpaced revenue increases at times, reducing efficiency. The recent moderate recovery in asset turnover indicates management efforts to better align revenue generation with asset utilization. There were minor quarters with dips in revenues and assets, but they do not detract from the overall expanding trend. This financial behavior highlights growth accompanied by ongoing challenges in optimizing asset productivity.
Equity Turnover
Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | |||||||||||||||||||||||||||||
Revenues | |||||||||||||||||||||||||||||
Shareholders’ equity | |||||||||||||||||||||||||||||
Long-term Activity Ratio | |||||||||||||||||||||||||||||
Equity turnover1 | |||||||||||||||||||||||||||||
Benchmarks | |||||||||||||||||||||||||||||
Equity Turnover, Competitors2 | |||||||||||||||||||||||||||||
AbbVie Inc. | |||||||||||||||||||||||||||||
Amgen Inc. | |||||||||||||||||||||||||||||
Bristol-Myers Squibb Co. | |||||||||||||||||||||||||||||
Danaher Corp. | |||||||||||||||||||||||||||||
Eli Lilly & Co. | |||||||||||||||||||||||||||||
Gilead Sciences Inc. | |||||||||||||||||||||||||||||
Johnson & Johnson | |||||||||||||||||||||||||||||
Merck & Co. Inc. | |||||||||||||||||||||||||||||
Pfizer Inc. | |||||||||||||||||||||||||||||
Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||||||||
Thermo Fisher Scientific Inc. |
Based on: 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q2 2025 Calculation
Equity turnover
= (RevenuesQ2 2025
+ RevenuesQ1 2025
+ RevenuesQ4 2024
+ RevenuesQ3 2024)
÷ Shareholders’ equity
= ( + + + )
÷ =
2 Click competitor name to see calculations.
The financial data reveals several key trends over the analyzed periods. Revenues consistently increased from March 2020 through June 2024, with some fluctuations in growth rates. Starting at approximately $1,515,107 thousand in March 2020, revenues reached a peak near $2,912,000 thousand by December 2024 before showing a slight decline in March and June 2025.
Shareholders’ equity exhibited a strong upward trajectory from approximately $6,461,654 thousand at the beginning of the period to a high point of around $18,546,600 thousand by mid-2024. However, after reaching this peak, equity experienced a decline toward the later quarters, falling back to roughly $16,309,000 thousand in June 2024 before partially recovering to about $17,175,400 thousand by mid-2025.
Equity turnover, which measures how efficiently equity is used to generate revenues, displays a varied pattern with an initial stable phase around 0.71 to 0.75 through 2020 into early 2021, followed by a gradual decline down to approximately 0.55-0.58 during mid-2022 to mid-2023, suggesting a reduction in efficiency. This was succeeded by a partial recovery around 0.66-0.70 in the most recent quarters, indicating an improvement in equity utilization.
- Revenue Trends
- Revenues showed steady growth through nearly all periods, more than doubling over five years, with minor dips at the very end.
- Shareholders’ Equity Dynamics
- Equity steadily increased along with revenues, maintaining a generally positive trend until mid-2024. A notable dip follows, indicative of possible equity adjustments or share repurchases.
- Equity Turnover Ratio
- Equity turnover began strong but declined gradually, implying that revenue growth was outpaced by equity increase during mid-periods. A recent reversal suggests improved operational efficiency.